F8IL10 not checked

Philogen S.p.A.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
3 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Rheumatoid Arthritis (RA)
Main trialPhase 1
“The aim of this study is to evaluate the safety of F8IL10 when administered by intra-articular injection and to determine the maximum tolerated dose (MTD) in order to establish the recommended dose (RD) in patients with Reumatoid Arthritis.”In the company’s words, NCT07245992 on ClinicalTrials.gov
Other names
Dekavil

Other drugs for Rheumatoid Arthritis (RA)

All 79 drugs for Rheumatoid Arthritis (RA)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 30 Sep 2028 A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis
Phase 2Terminated Apr 2019 A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX
Phase 1Withdrawn 31 Dec 2025 Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow F8IL10

Following is part of Solo: you see every change to F8IL10 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in